Astellas Pharma US | Changing Tomorrow

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib) Read More

Check out The Astellas Way Blog to hear our executives' thoughts on moments and trends in the industry and what's on the horizon for our company

Astellas Announces Collaboration with the Jewish Association Serving the Aging (JASA) to Improve Chronic Disease and Bladder Health Management Read More

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

Astellas Announces Key Leadership Appointments within Oncology and Patient Centricity Organizations Read More

Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts Read More

News

Latest

News / Media

Sep 02, 2019

RIKEN and Astellas Enter into Worldwide Exclusive Licensing Agreement for Artificial Adjuvant Vector Cell Technology in Oncology

News / Media

Aug 09, 2019

Yokohama City University, Tokyo University of the Arts and Astellas Launched Health Mock Lab. to Create New Digital Healthcare Solutions Using Gamification

News / Media

Aug 06, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

News / Corporate

Sep 16, 2019

Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

News / Corporate

Sep 12, 2019

Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

News / Our People

Aug 27, 2019

Astellas Announces Key Leadership Appointments within Oncology and Patient Centricity Organizations

View All >>